iTeos Therapeutics, Inc. (ITOS)

NASDAQ: ITOS · IEX Real-Time Price · USD
10.79
+0.23 (2.18%)
Apr 22, 2024, 4:00 PM EDT - Market closed
2.18%
Market Cap 386.75M
Revenue (ttm) 12.60M
Net Income (ttm) -112.64M
Shares Out 35.84M
EPS (ttm) -3.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 174,072
Open 10.65
Previous Close 10.56
Day's Range 10.45 - 11.16
52-Week Range 8.20 - 18.24
Beta 1.19
Analysts Strong Buy
Price Target 33.25 (+208.16%)
Earnings Date May 8, 2024

About ITOS

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 157
Stock Exchange NASDAQ
Ticker Symbol ITOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ITOS stock is "Strong Buy." The 12-month stock price forecast is $33.25, which is an increase of 208.16% from the latest price.

Price Target
$33.25
(208.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...

15 days ago - GlobeNewsWire

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...

6 weeks ago - GlobeNewsWire

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose coho...

6 weeks ago - GlobeNewsWire

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...

6 weeks ago - GlobeNewsWire

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...

7 weeks ago - GlobeNewsWire

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

5 months ago - GlobeNewsWire

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC  - Completed enrollment of monotherapy dose e...

5 months ago - GlobeNewsWire

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,...

Other symbols: GILDRHHBYRCUS
8 months ago - Market Watch

iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination

9 months ago - GlobeNewsWire

iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates

–  Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens

1 year ago - GlobeNewsWire

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupa...

1 year ago - GlobeNewsWire

iTeos to Present at Cowen 43rd Annual Health Care Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

1 year ago - GlobeNewsWire

iTeos to Present at SVB Securities Global Biopharma Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

1 year ago - GlobeNewsWire

iTeos Provides Business Updates and Clinical Development Plans for 2023

- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant

1 year ago - GlobeNewsWire

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

1 year ago - GlobeNewsWire

iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

1 year ago - GlobeNewsWire

iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates

– Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK's anti-PD-1 Jemperli (dostarlimab) in first line, metastatic non-small cell lung cancer

1 year ago - GlobeNewsWire

iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update

- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A, and GSK's anti-PD-1 Jemperli (dostarlim...

1 year ago - GlobeNewsWire

iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

1 year ago - GlobeNewsWire

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

STRASBOURG, France & MONTREAL, Canada--(BUSINESS WIRE)--Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Re...

2 years ago - Business Wire

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

WATERTOWN, Mass. and GOSSELIES, Belgium, May 12, 2022 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

2 years ago - GlobeNewsWire

Innoskel Appoints Dr Michel Detheux as Chairman

Inno s kel Appoints Dr Michel Detheux as Chairman

2 years ago - GlobeNewsWire

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

WATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...

2 years ago - GlobeNewsWire

iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab -gxly) and EOS-448 combination trial and announced plans to initiate multiple reg...

2 years ago - GlobeNewsWire

iTeos to Present at the Cowen 42nd Annual Health Care Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...

2 years ago - GlobeNewsWire